[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

Padmanee Sharma (born June 26, 1970) is an immunologist and oncologist at the University of Texas MD Anderson Cancer Center in Houston, Texas. She holds the position of professor of genitourinary medical oncology and immunology in the Division of Cancer Medicine where she specializes in renal, prostate, and bladder cancers.

Dr. Padmanee Sharma, Director of Scientific Programs for James P. Allison Institute and Scientific Director of Immunotherapy Platform at MD Anderson Cancer Center

Research

edit

Sharma studies the treatment of cancer with immunotherapy.[1][2][3] Her doctoral work demonstrated that cells expressing thymus-leukemia (TL) on their surface could be recognized by the Immune system and killed.[4] In 2003, she was the lead author on a study of another tumor antigen, NY-ESO-1 in bladder cancer.[5] She won an ASCO Young Investigator Award in 2003 to pursue this work.[6]

Education

edit

Honors

edit
  • 2018 William B. Coley Award for Distinguished Research in Tumor Immunology[7]
  • 2008 Prostate Cancer Foundation Challenge Award[8]
  • 2003 ASCO Young Investigator Award[9]
  • 2002 Doris Duke Clinical Scientist Development Award[10]

Personal life

edit

Sharma was born June 26, 1970, in Guyana.[11] She is married to longtime collaborator, James P. Allison and has three daughters from a previous marriage.[12]

References

edit
  1. ^ "Parker-backed cancer scientists shine a light on an emerging pathway in pancreatic cancer". endpts.com. Endpoints News. Retrieved 3 February 2019.
  2. ^ "Sharma Stresses Importance of Refining Immunotherapy in GU Cancers". Onclive.com. OncLive. Retrieved 3 February 2019.
  3. ^ Sharma, Padmanee; Allison, James P. (2015). "The future of immune checkpoint therapy". Science. 348 (6230): 56–61. doi:10.1126/science.aaa8172. PMID 25838373. S2CID 4608450.
  4. ^ Sharma, P.; Joyce, S.; Chorney, K. A.; Griffith, J. W.; Bonneau, R. H.; Wilson, F. D.; Johnson, C. A.; Flavell, R. A.; Chorney, M. J. (February 1, 1996). "hymus-leukemia antigen interacts with T cells and self-peptides". The Journal of Immunology. 156 (3): 987–996. doi:10.4049/jimmunol.156.3.987. PMID 8558026. S2CID 33666133.
  5. ^ "Frequency of NY-ESO-1 and LAGE-1 expression in bladder cancer and evidence of a new NY-ESO-1 T-cell epitope in a patient with bladder cancer". Cancer Immunity Archive. 3 (1): 19. January 2003.
  6. ^ "Grant & Award Recipients". conquer.org. The ASCO Foundation. Retrieved 3 February 2019.
  7. ^ "Three Scientists to Receive Top Honors from the Cancer Research Institute for Outstanding Contributions to Cancer Immunology and Immunotherapy". cancerresearch.org. Cancer Research Institute. Retrieved 3 February 2019.
  8. ^ "Challenge Awards-Class of 2008". pcf.org. Prostate Cancer Foundation.
  9. ^ "Grant & Award Recipients". conquer.org. The ASCO Foundation. Retrieved 3 February 2019.
  10. ^ "Doris Duke Charitable Foundation 10th Anniversary Report" (PDF). ddcf.org. Retrieved 3 February 2019.
  11. ^ "Professor Padmanee Sharma". What is Biotechnology?. Retrieved 3 February 2019.
  12. ^ "Cancer-fighting power couple tackles mysteries of the immune system". Washington Post. Retrieved 3 February 2019.